Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer
Open Access
- 1 June 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (6) , 848-855
Abstract
Locally advanced non–small cell lung cancer (NSCLC) accounts for 20% to 25% of new diagnoses of NSCLC.1 The historical 5-year overall survival rate for definitive concurrent chemoradiotherapy for locally advanced NSCLC was 25% to 30%.2-4 Recently, consolidative programmed death ligand-1 (PD-L1) inhibition using durvalumab after chemoradiotherapy improved progression-free survival (PFS) and 3-year overall survival to 57.0% compared with 43.5% for chemoradiotherapy alone.5,6Keywords
This publication has 28 references indexed in Scilit:
- Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An Analysis of Veterans Health Administration DataJournal of Clinical Oncology, 2015
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyThe Lancet Oncology, 2015
- Combinations of Immunotherapy and Radiation in Cancer TherapyFrontiers in Oncology, 2014
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- Effects of conventional therapeutic interventions on the number and function of regulatory T cellsOncoImmunology, 2013
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancerCell Death & Differentiation, 2013
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI: Journal of the National Cancer Institute, 2011
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009